Stephen Basil Thomas
Director at Climb Bio, Inc. (CLYM)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $2.2M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Sep 17SEC | CLYMClimb Bio, Inc. | Sell Plan | 100,000467,969 held (−18%) | $13.67 | $1.4M | -19.5% |
| Feb 27SEC | CLYMClimb Bio, Inc. | Sell Plan | 33,687170,970 held (−16%) | $7.00 | $236K | +57.1% |
| Feb 27SEC | CLYMClimb Bio, Inc. | Sell Plan | 16,313154,657 held (−10%) | $7.01 | $114K | +56.9% |
| Feb 17SEC | CLYMClimb Bio, Inc. | Sell Plan | 90,000214,657 held (−30%) | $5.23 | $471K | +110.3% |
| Feb 17SEC | CLYMClimb Bio, Inc. | Sell Plan | 10,000204,657 held (−5%) | $5.81 | $58K | +89.3% |
- Sell
Director Stephen Basil Thomas sold $1.4M of CLYM at $13.67 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Stephen Basil Thomas sold $236K of CLYM at $7.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Stephen Basil Thomas sold $114K of CLYM at $7.01 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Stephen Basil Thomas sold $471K of CLYM at $5.23 — cuts the stake by 30%; pre-scheduled 10b5-1 plan sale.
- Sell
Director Stephen Basil Thomas sold $58K of CLYM at $5.81 — pre-scheduled 10b5-1 plan sale.